Replies to post #22096 on RespireRx Pharmaceuticals Inc (fka RSPI)

[iggs]

Given the large holdings of those of us on this board, we should have board representation. Not sure if this could be done, but I would say that we collectively could give our vote over to Neuro and ask the Company to provide him with a board seat.

Thoughts....? I, for one, would vote for that.

Iggs

[asuhowe]

Neuro, thanks for taking the time to do a 2-year analysis.. I actually feel a bit better that it is more of a sector swoon than just one tainted stock..
I am assuming that like every sector, there are ebbs and flows.. I think the key for COR now is a duck and cover mode.. get a decent deal for RD so they can sustain research and development activities over the next few years, package together a nice suite of offerings, let the market stabalize, and then strike something pps effecting when the time is right..

Patience Patience Patience is the name of the game now..
Thankfully we at least have something to offer a BP.. We could be sitting here with nothing but 'promise' ...

cheers..

[gfp927z]

Neuro, Nice call on MEMY, from 11-9-08 -

>>> MEMY looks like a buyout/merger candidate to me <<<


>>> Memory Pharma--how a company with what looks like a successful nicotinic partnership with Roche, and an ambiguous partnership with Amgen, can be trading below cash is baffling. It's the Icarus phenomenon--their valuation at one time was bizarrely inflated due to the Kandel/Nobel Prize affiliation. Now they have fallen, and too far. They have some cash but they're burning it: One problem is that they are using money on projects that aren't seen as promising anymore, like PDE4. Even with milestones coming from Roche, the cash only lasts into 2Q:08. Obviously, the delisting process hurt badly. (People don't realize that Cortex being on AMEX has some real advantages at times like this). MEMY looks like a buyout/merger candidate to me, though Roche's ownership of their best asset restricts the range of potential acquirers greatly. <<<